FABPI抗体;FABPI Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of intestinal FABP expression in Human small intestine lysate.    

  
  

Fatty acid-binding protein 1 (FABP1), also known as liver-type FABP (L-FABP), is a small cytosolic protein primarily expressed in the liver, intestine, and kidney. It plays a key role in intracellular fatty acid transport, metabolism, and signaling by binding hydrophobic ligands such as long-chain fatty acids, eicosanoids, and bile acids. FABP1 antibodies are immunological tools designed to detect and quantify this protein in research and diagnostic applications.

These antibodies are widely used to study FABP1's involvement in metabolic disorders (e.g., obesity, diabetes), liver diseases (steatosis, hepatitis), intestinal inflammation, and cancer progression. Commercial FABP1 antibodies are typically developed in hosts like rabbits or mice, targeting specific epitopes through immunogen peptides or recombinant proteins. Validation methods include Western blotting, immunohistochemistry (IHC), and ELISA to ensure specificity across human, mouse, or rat samples.

Clinically, FABP1 serves as a biomarker for tissue injury; elevated serum levels indicate hepatocellular damage or intestinal ischemia. Research-grade antibodies help unravel FABP1's dual role in cytoprotection (e.g., mitigating oxidative stress) and disease pathogenesis. However, variability in antibody performance across commercial sources and assay conditions necessitates rigorous validation. Advances in recombinant antibody engineering and multiplex assays continue to enhance FABP1 detection sensitivity and specificity for translational studies.